Brought to you by 
Forty Seven nets $81mm in public offering
30 Mar 2021
Executive Summary
Oncology firm Forty Seven Inc. netted $81mm through a public offering of 10.78mm common shares (including the overallotment) at $8. Funds will support continued development of lead candidate 5F9, an anti-CD47 antibody in various clinical trials for solid and blood cancers. Earlier this month, Ono licensed exclusive rights to develop and sell 5F9 in Japan, South Korea, Taiwan, and the ASEAN countries.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Forty Seven nets $81mm in public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice